Tiziana Life Sciences PLC Announces Approval of a Phase II Clinical Trial
April 24 2017 - 1:14AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
24 April 2017
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Life Sciences Announces Approval of a Phase II Clinical
Trial Protocol for Milciclib in Patients with Hepatocellular
Carcinoma
In mouse models of HCC, oral administration with milciclib
effectively suppressed tumour growth
London, 24 April, 2017 - Tiziana Life Sciences plc (AIM: TILS),
a clinical stage biotechnology company developing targeted drugs
for cancer and autoimmune diseases, today announces the approval in
Israel of a phase II clinical trial protocol for testing milciclib,
a novel inhibitor of cell cycle dependent kinases (CDKs), in
patients with refractory hepatocellular carcinoma ("HCC"). A
similar clinical trial protocol has been submitted for approval in
Italy, Turkey and Greece. The primary objective of these
multi-centered, multi-country and dose-ranging phase IIa clinical
studies is to evaluate the safety of milciclib in HCC patients who
fail to respond or are intolerant to the existing standard of care
treatment. First patient enrollment is expected next month and top
line data from the trial is expected by Q3 2018.
In previous clinical studies, oral treatment with milciclib was
found to be safe and well-tolerated in patients with refractory
solid tumours, thymoma and thymic cancers. Data from animal studies
has demonstrated that oral administration with milciclib
effectively suppressed tumour growth in mouse models of HCC.
Although the precise mode of action is not clearly understood, the
preclinical studies conducted strongly suggest that milciclib acts
primarily through downregulation of microRNA (miR) 221 and 222,
which are known to be associated with hepatocarcinogenesis.
Overexpression of miR-221 and miR-222 is also believed to be
associated with development of resistance to sorafenib (NexavarÃ’)
in HCC patients
Gabriele Cerrone, Chairman of Tiziana commented: "HCC is a real
unmet medical need due to its growing incidence and lack of
effective therapy. It is the fifth most common cancer worldwide and
the second most common cause of death from cancer worldwide. We
strongly believe that milciclib has the potential to be developed
either as a monotherapy or in combination with sorafenib for
treatment of HCC."
Dr. Yaron Ilan, Director of the Department of Medicine at Hebrew
University Hadassah Medical Center, Israel and Chief Medical
Officer of Tiziana added: "The prognosis for liver cancer is very
poor due to lack of effective therapy. We were very encouraged with
recent pre-clinical findings and are now moving forward to conduct
a phase II clinical trial in HCC patients with milciclib in
patients that failed to respond to the standard of care therapy. We
believe that milciclib holds promise as an effective anti-cancer
treatment with a high safety profile."
About HCC
Hepatocellular carcinoma is the fifth most common cancer in men
and the ninth in women. Additionally, it is the fifth most common
cancer worldwide and the second most common cause of death from
cancer worldwide.[1] The tumour is associated with chronic
hepatitis B and chronic hepatitis C infections, as well as with
nonalcoholic steatohepatitis. The prognosis for liver cancer is
very poor due to lack of effective therapy.
About Milciclib
Milciclib (PHA-848125AC) is a small molecule inhibitor of
several cyclin dependent kinases (CDKs) such as CDK1, CDK4, CDK5
and CDK7. CDKs are serine threonine kinases that play crucial roles
in progression of the cell cycle from G(1) to S phase.
Overexpression of CDKs and other downstream signaling pathways that
regulate cell cycles have been frequently found to be associated
with development of resistance towards chemotherapies. Oral
treatment with milciclib was found to be effective in reducing
tumour growth in animal models of HCC, possibly through
downregulation of miR-221 and miR-222. In a phase I study, oral
treatment with milciclib was found to be well-tolerated and the
drug showed promising clinical responses in patients with advanced
solid malignancies such as in thymic carcinoma, pancreatic
carcinoma and colon cancer.
About Yaron Ilan, MD
Prof. Yaron Ilan is the Director of the Department of Medicine
at the Hadassah-Hebrew University Medical Center in Jerusalem
Israel and served as the Vice Dean of the Hebrew
University-Hadassah Medical School. He has pioneered the
development of oral immunotherapy for HCC, NASH, diabetes, and
inflammatory bowel diseases. He developed several products which
target the immune system of the gastrointestinal tract as a mean
for alleviating immune-mediated disorders without the need for
immunosuppression. He holds over 50 patents for discoveries based
on his research mainly in oral immunotherapy and mucosal
immunology. His clinical interests are in the management of NASH
and diabetes by targeting the inflammation-associated with these
diseases by using products with high safety profile enabling their
chronic use. He is involved in multiple clinical trials using oral
immunotherapy-based compounds.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules that
treat human disease in oncology and immunology. The Company is
focused on its lead compound milciclib. The Company is also in
clinical development of foralumab. Foralumab is the only fully
human engineered anti-human CD3 antibody in clinical development.
This phase II compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBS),
ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D),
inflammatory bowel disease (IBD), psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable.
For more information go to
http://www.tizianalifesciences.com
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
Contacts
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser) +44 (0)20 7213
Liam Murray 0883
Beaufort Securities Limited (Broker)
Saif Janjua +44 (0)20 7382 8300
FTI Consulting
Simon Conway / Natalie Garland-Collins +44 (0)20 3727 1000
[1] http://www.who.int/mediacentre/factsheets/fs297/en/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAMMGZDVDZGNZG
(END) Dow Jones Newswires
April 24, 2017 02:14 ET (06:14 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024